Search Results - "Bertucci, François"

Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer by Xiao, Yi, Ma, Ding, Zhao, Shen, Suo, Chen, Shi, Jinxiu, Xue, Meng-Zhu, Ruan, Miao, Wang, Hai, Zhao, Jingjing, Li, Qin, Wang, Peng, Shi, Leming, Yang, Wen-Tao, Huang, Wei, Hu, Xin, Yu, Ke-Da, Huang, Shenglin, Bertucci, François, Jiang, Yi-Zhou, Shao, Zhi-Ming

“…The tumor microenvironment has a profound impact on prognosis and immunotherapy. However, the landscape of the triple-negative breast cancer (TNBC)…”
Get full text

Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1 by Bertucci, François, Gonçalves, Anthony

“…Purpose of Review The purpose of the review is to summarize the data regarding PD-L1 expression in breast cancer and the results of first clinical trials with…”
Get full text

Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity by Mamessier, Emilie, Sylvain, Aude, Thibult, Marie-Laure, Houvenaeghel, Gilles, Jacquemier, Jocelyne, Castellano, Rémy, Gonçalves, Anthony, André, Pascale, Romagné, François, Thibault, Gilles, Viens, Patrice, Birnbaum, Daniel, Bertucci, François, Moretta, Alessandro, Olive, Daniel

“…NK cells are a major component of the antitumor immune response and are involved in controlling tumor progression and metastases in animal models. Here, we…”
Get full text

Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers by de Nonneville, Alexandre, Houvenaeghel, Gilles, Cohen, Monique, Sabiani, Laura, Bannier, Marie, Viret, Frederic, Gonçalves, Anthony, Bertucci, François

“…Half of HER2-negative breast cancers (BC) show HER2-low expression. The strong efficacy of recent anti-HER2 antibody–drug conjugates (ADC) in HER2-low tumours…”
Get full text

PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond? by Gonçalves, Anthony, Bertucci, Alexandre, Bertucci, François

“…Exquisitely exploiting defects in homologous recombination process, poly(ADP-ribose) polymerase (PARP) inhibitors have recently emerged as a promising class of…”
Get full text

RE: HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 by Bertucci, François, de Nonneville, Alexandre, Finetti, Pascal, Mamessier, Emilie

Get full text

Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements by Bertucci, Alexandre, Bertucci, François, Gonçalves, Anthony

“…The phosphatidylinositol 3-kinase (PI3K) pathway is one of the most altered pathways in human cancers, and it plays a central role in cellular growth,…”
Get full text

miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy by Rodriguez-Barrueco, Ruth, Nekritz, Erin A, Bertucci, François, Yu, Jiyang, Sanchez-Garcia, Felix, Zeleke, Tizita Z, Gorbatenko, Andrej, Birnbaum, Daniel, Ezhkova, Elena, Cordon-Cardo, Carlos, Finetti, Pascal, Llobet-Navas, David, Silva, Jose M

“…The female mammary gland is a very dynamic organ that undergoes continuous tissue remodeling during adulthood. Although it is well established that the number…”
Get full text

How basal are triple‐negative breast cancers? by Bertucci, François, Finetti, Pascal, Cervera, Nathalie, Esterni, Benjamin, Hermitte, Fabienne, Viens, Patrice, Birnbaum, Daniel

“…The basal molecular subtype of breast cancer (BC) is defined by the mRNA expression pattern of an intrinsic ∼500‐gene set. It is the most homogeneous subtype…”
Get full text

Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer by CHARAFE-JAUFFRET, Emmanuelle, GINESTIER, Christophe, XERRI, Luc, DONTU, Gabriela, STASSI, Giorgio, YI XIAO, BARSKY, Sanford H, BIRNBAUM, Daniel, VIENS, Patrice, WICHA, Max S, IOVINO, Flora, TARPIN, Carole, DIEBEL, Mark, ESTERNI, Benjamin, HOUVENAEGHEL, Gilles, EXTRA, Jean-Marc, BERTUCCI, François, JACQUEMIER, Jocelyne

“…Purpose: To examine the role of cancer stem cells (CSC) in mediating metastasis in inflammatory breast cancer (IBC) and the association of these cells with…”
Get full text

Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives? by Nicolas, Emanuel, Bertucci, François, Sabatier, Renaud, Gonçalves, Anthony

“…Breast cancers (BC) associated with germline mutations of represent 3⁻5% of cases. -associated BC have biological features leading to genomic instability and…”
Get full text

Personalized medicine: Present and future of breast cancer management by Sabatier, Renaud, Gonçalves, Anthony, Bertucci, François

“…Abstract Breast cancer is the first cause of cancer in women worldwide. Recent molecular analyses have shown that it is not a single disease but a mixture of…”
Get full text

Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results by Goncalves, Anthony, Mezni, Essia, Bertucci, François

“…PURPOSE OF REVIEWRecently, both immune checkpoint inhibitors and poly(ADP-ribose) polymerase inhibitors have demonstrated clinical benefit in some subsets of…”
Get full text

Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors by Birnbaum, David Jérémie, Bertucci, François, Finetti, Pascal, Birnbaum, Daniel, Mamessier, Emilie

“…The association between pancreatic ductal adenocarcinoma (PDAC) location (head vs. Body/Tail (B/T)) and clinical outcome remains controversial. We collected…”
Get full text

The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtype by Bertucci, François, Finetti, Pascal, Goncalves, Anthony, Birnbaum, Daniel

“…The genomics-based molecular classifications aim at identifying more homogeneous classes than immunohistochemistry, associated with a more uniform clinical…”
Get full text

Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer by Allensworth, Jennifer L., Evans, Myron K., Bertucci, François, Aldrich, Amy J., Festa, Richard A., Finetti, Pascal, Ueno, Naoto T., Safi, Rachid, McDonnell, Donald P., Thiele, Dennis J., Van Laere, Steven, Devi, Gayathri R.

“…Cancer cells often have increased levels of reactive oxygen species (ROS); however, acquisition of redox adaptive mechanisms allows for evasion of ROS-mediated…”
Get full text

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial by Mir, Olivier, MD, Cropet, Claire, MSc, Toulmonde, Maud, MD, Cesne, Axel Le, MD, Molimard, Mathieu, Prof, Bompas, Emmanuelle, MD, Cassier, Philippe, MD, Ray-Coquard, Isabelle, Prof, Rios, Maria, MD, Adenis, Antoine, Prof, Italiano, Antoine, MD, Bouché, Olivier, Prof, Chauzit, Emmanuelle, PharmD, Duffaud, Florence, Prof, Bertucci, François, Prof, Isambert, Nicolas, MD, Gautier, Julien, MSc, Blay, Jean-Yves, Prof, Pérol, David, MD

“…Summary Background Gastrointestinal stromal tumours (GIST) are the most common mesenchymal neoplasms of the gastrointestinal tract. Imatinib followed by…”
Get full text

SPAG5 : the ultimate marker of proliferation in early breast cancer? by Bertucci, François, Viens, Patrice, Birnbaum, Daniel

“…[...]multigene classifiers identified from gene expression analyses and other proliferation markers, such as Ki67, have been incorporated in the Saint-Gallen…”
Get full text

Wnt Signaling Inhibition Promotes Apoptosis in Sarcomas-Letter by Bertucci, François, Finetti, Pascal, Birnbaum, Daniel

Get full text

EFA6B regulates a stop signal for collective invasion in breast cancer by Fayad, Racha, Rojas, Monserrat Vázquez, Partisani, Mariagrazia, Finetti, Pascal, Dib, Shiraz, Abelanet, Sophie, Virolle, Virginie, Farina, Anne, Cabaud, Olivier, Lopez, Marc, Birnbaum, Daniel, Bertucci, François, Franco, Michel, Luton, Frédéric

“…Cancer is initiated by somatic mutations in oncogenes or tumor suppressor genes. However, additional alterations provide selective advantages to the tumor…”
Get full text